DoD Allocates FY2026 Funding for Humacyte’s Symvess After 100% Survival in Ukraine
The FY2026 U.S. Department of Defense Appropriations Act assigns dedicated funding for evaluating Humacyte’s FDA-approved Symvess bioengineered blood vessels for battlefield vascular repair. Symvess achieved 100% survival, zero amputations and zero conduit infections in a 16-patient retrospective study of wartime injuries in Ukraine.
1. DoD Funding for Symvess
The FY2026 Department of Defense Appropriations Act includes earmarked funds to procure and evaluate Humacyte’s Symvess bioengineered blood vessels for treatment of traumatic extremity arterial injuries when autologous vein harvesting is not feasible.
2. Battlefield Clinical Data
In a humanitarian program in Ukraine, 16 service members with gunshot, shrapnel and blast injuries received Symvess in a retrospective observational study, yielding 100% survival, zero amputations and no conduit infections despite severe trauma.
3. FDA Approval and Indications
Symvess is the only human-derived bioengineered vessel approved by the U.S. Food and Drug Administration for urgent extremity arterial revascularization, with additional investigational applications pending regulatory clearance.
4. Commercial and Strategic Impact
This first-of-its-kind federal investment validates Humacyte’s technology in military medicine and may establish a recurring government procurement channel, enhancing revenue prospects and bolstering the company’s long-term valuation.